Cargando…
The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
BACKGROUND: Ustekinumab is a fully human monoclonal antibody approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults. However, factors including efficacy, tolerability, ease of use, and cost burden may affect ustekinumab utilization. Noncompliance may, in turn, affect tre...
Autores principales: | Youn, Sang Woong, Tsai, Tsen-Fang, Theng, Colin, Choon, Siew-Eng, Wiryadi, Benny E., Pires, Antonio, Tan, Weihao, Lee, Min-Geol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828387/ https://www.ncbi.nlm.nih.gov/pubmed/27081271 http://dx.doi.org/10.5021/ad.2016.28.2.222 |
Ejemplares similares
-
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022) -
Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009) -
Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
por: Choi, Chong Won, et al.
Publicado: (2018) -
Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010) -
Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)